Tomoyuki Igawa, Ph.D., is currently the Chief Executive Officer of Chugai Pharamabody Research in Singapore. He has started working at Chugai Pharmaceutical as a Research scientist and had experiences as a project leader for emicizumab and natalizumab. He graduated and awarded PhD from the University of Tokyo for studies in Engineering, Chemistry and Biotechnology.
After a couple of year as Research Scientist working on early CMC development and pharmacokinetics, he focused on antibody engineering which leads to the discovery of bispecific antibody Hemlibra (emicizumab) for haemophilia A, recycling antibody and sweeping antibody technology for various applications. Recent years he has been responsible for biologics drug discovery and cancer immunotherapy discovery. Dr.Igawa likes to work in the area of an interface between antibody technology and disease mechanism especially for unmet needs in the world.